Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN003 in Advanced Solid Tumors
NCT02961283Phase 1Terminated
- Sponsor
- Asana BioSciences, LLC
- Start
- Oct 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASN003 in solid tumor (advanced stage), melanoma, colorectal cancer (CRC) and 1 more (4 arms), sponsored by Asana BioSciences, LLC. Primary endpoints: Maximum Tolerated Dose and Preliminary Efficacy up to 1 year. Started Oct 2016; status: terminated.
02
Drugs
ASN003
03
Conditions
solid tumor (advanced stage)melanomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02961283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961283.